Financhill
Sell
8

CLRB Quote, Financials, Valuation and Earnings

Last price:
$4.85
Seasonality move :
-13.76%
Day range:
$4.80 - $5.05
52-week range:
$4.36 - $94.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
137.94x
P/B ratio:
1.14x
Volume:
61.7K
Avg. volume:
901.5K
1-year change:
-93.41%
Market cap:
$8.8M
Revenue:
--
EPS (TTM):
-$21.90

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CLRB
Cellectar Biosciences
-- -$3.60 -- -31.48% $4.00
ARAY
Accuray
$97.8M -$0.04 -7.31% -50% $5.17
INTS
Intensity Therapeutics
-- -$0.18 -- -50% $3.50
MGNX
Macrogenics
$28.1M $0.38 159.87% -25.84% $4.20
OGEN
Oragenics
-- -- -- -- $1.00
PODD
Insulet
$612.3M $0.93 25.31% -64.13% $336.01
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CLRB
Cellectar Biosciences
$4.88 $4.00 $8.8M -- $0.00 0% 137.94x
ARAY
Accuray
$1.36 $5.17 $140.1M -- $0.00 0% 0.30x
INTS
Intensity Therapeutics
$0.33 $3.50 $6.1M -- $0.00 0% --
MGNX
Macrogenics
$1.61 $4.20 $101.6M -- $0.00 0% 0.66x
OGEN
Oragenics
$1.42 $1.00 $1M -- $0.00 0% 0.45x
PODD
Insulet
$289.32 $336.01 $20.4B 52.04x $0.00 0% 9.73x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CLRB
Cellectar Biosciences
-- 0.590 -- --
ARAY
Accuray
77.8% 2.035 94.39% 0.82x
INTS
Intensity Therapeutics
-- 1.007 -- --
MGNX
Macrogenics
-- 0.939 -- 2.97x
OGEN
Oragenics
-- 0.068 -- --
PODD
Insulet
56.03% 1.967 9.18% 3.24x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CLRB
Cellectar Biosciences
-- -$6.4M -- -- -- -$9.4M
ARAY
Accuray
$31.6M $1M 0.31% 1.47% 1.81% $15.6M
INTS
Intensity Therapeutics
-- -$3.4M -- -- -- -$2M
MGNX
Macrogenics
$7.8M -$42.6M -58.23% -58.23% -310.38% -$47.4M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M

Cellectar Biosciences vs. Competitors

  • Which has Higher Returns CLRB or ARAY?

    Accuray has a net margin of -- compared to Cellectar Biosciences's net margin of -1.15%. Cellectar Biosciences's return on equity of -- beat Accuray's return on equity of 1.47%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLRB
    Cellectar Biosciences
    -- -$4.20 --
    ARAY
    Accuray
    27.93% -$0.01 $223.4M
  • What do Analysts Say About CLRB or ARAY?

    Cellectar Biosciences has a consensus price target of $4.00, signalling upside risk potential of 2359.02%. On the other hand Accuray has an analysts' consensus of $5.17 which suggests that it could grow by 279.9%. Given that Cellectar Biosciences has higher upside potential than Accuray, analysts believe Cellectar Biosciences is more attractive than Accuray.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLRB
    Cellectar Biosciences
    2 2 0
    ARAY
    Accuray
    2 0 0
  • Is CLRB or ARAY More Risky?

    Cellectar Biosciences has a beta of 0.507, which suggesting that the stock is 49.315% less volatile than S&P 500. In comparison Accuray has a beta of 1.260, suggesting its more volatile than the S&P 500 by 25.978%.

  • Which is a Better Dividend Stock CLRB or ARAY?

    Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Accuray pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLRB or ARAY?

    Cellectar Biosciences quarterly revenues are --, which are smaller than Accuray quarterly revenues of $113.2M. Cellectar Biosciences's net income of -$6.6M is lower than Accuray's net income of -$1.3M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Accuray's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 137.94x versus 0.30x for Accuray. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLRB
    Cellectar Biosciences
    137.94x -- -- -$6.6M
    ARAY
    Accuray
    0.30x -- $113.2M -$1.3M
  • Which has Higher Returns CLRB or INTS?

    Intensity Therapeutics has a net margin of -- compared to Cellectar Biosciences's net margin of --. Cellectar Biosciences's return on equity of -- beat Intensity Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLRB
    Cellectar Biosciences
    -- -$4.20 --
    INTS
    Intensity Therapeutics
    -- -$0.22 --
  • What do Analysts Say About CLRB or INTS?

    Cellectar Biosciences has a consensus price target of $4.00, signalling upside risk potential of 2359.02%. On the other hand Intensity Therapeutics has an analysts' consensus of $3.50 which suggests that it could grow by 951.05%. Given that Cellectar Biosciences has higher upside potential than Intensity Therapeutics, analysts believe Cellectar Biosciences is more attractive than Intensity Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLRB
    Cellectar Biosciences
    2 2 0
    INTS
    Intensity Therapeutics
    1 2 0
  • Is CLRB or INTS More Risky?

    Cellectar Biosciences has a beta of 0.507, which suggesting that the stock is 49.315% less volatile than S&P 500. In comparison Intensity Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CLRB or INTS?

    Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intensity Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Intensity Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLRB or INTS?

    Cellectar Biosciences quarterly revenues are --, which are smaller than Intensity Therapeutics quarterly revenues of --. Cellectar Biosciences's net income of -$6.6M is lower than Intensity Therapeutics's net income of -$3.3M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Intensity Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 137.94x versus -- for Intensity Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLRB
    Cellectar Biosciences
    137.94x -- -- -$6.6M
    INTS
    Intensity Therapeutics
    -- -- -- -$3.3M
  • Which has Higher Returns CLRB or MGNX?

    Macrogenics has a net margin of -- compared to Cellectar Biosciences's net margin of -311.07%. Cellectar Biosciences's return on equity of -- beat Macrogenics's return on equity of -58.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLRB
    Cellectar Biosciences
    -- -$4.20 --
    MGNX
    Macrogenics
    59.07% -$0.65 $79.1M
  • What do Analysts Say About CLRB or MGNX?

    Cellectar Biosciences has a consensus price target of $4.00, signalling upside risk potential of 2359.02%. On the other hand Macrogenics has an analysts' consensus of $4.20 which suggests that it could grow by 160.87%. Given that Cellectar Biosciences has higher upside potential than Macrogenics, analysts believe Cellectar Biosciences is more attractive than Macrogenics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLRB
    Cellectar Biosciences
    2 2 0
    MGNX
    Macrogenics
    1 5 0
  • Is CLRB or MGNX More Risky?

    Cellectar Biosciences has a beta of 0.507, which suggesting that the stock is 49.315% less volatile than S&P 500. In comparison Macrogenics has a beta of 1.587, suggesting its more volatile than the S&P 500 by 58.67%.

  • Which is a Better Dividend Stock CLRB or MGNX?

    Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLRB or MGNX?

    Cellectar Biosciences quarterly revenues are --, which are smaller than Macrogenics quarterly revenues of $13.2M. Cellectar Biosciences's net income of -$6.6M is higher than Macrogenics's net income of -$41M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 137.94x versus 0.66x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLRB
    Cellectar Biosciences
    137.94x -- -- -$6.6M
    MGNX
    Macrogenics
    0.66x -- $13.2M -$41M
  • Which has Higher Returns CLRB or OGEN?

    Oragenics has a net margin of -- compared to Cellectar Biosciences's net margin of --. Cellectar Biosciences's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLRB
    Cellectar Biosciences
    -- -$4.20 --
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About CLRB or OGEN?

    Cellectar Biosciences has a consensus price target of $4.00, signalling upside risk potential of 2359.02%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Cellectar Biosciences has higher upside potential than Oragenics, analysts believe Cellectar Biosciences is more attractive than Oragenics.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLRB
    Cellectar Biosciences
    2 2 0
    OGEN
    Oragenics
    0 1 0
  • Is CLRB or OGEN More Risky?

    Cellectar Biosciences has a beta of 0.507, which suggesting that the stock is 49.315% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock CLRB or OGEN?

    Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLRB or OGEN?

    Cellectar Biosciences quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Cellectar Biosciences's net income of -$6.6M is lower than Oragenics's net income of -$2.2M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 137.94x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLRB
    Cellectar Biosciences
    137.94x -- -- -$6.6M
    OGEN
    Oragenics
    0.45x -- -- -$2.2M
  • Which has Higher Returns CLRB or PODD?

    Insulet has a net margin of -- compared to Cellectar Biosciences's net margin of 6.22%. Cellectar Biosciences's return on equity of -- beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLRB
    Cellectar Biosciences
    -- -$4.20 --
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About CLRB or PODD?

    Cellectar Biosciences has a consensus price target of $4.00, signalling upside risk potential of 2359.02%. On the other hand Insulet has an analysts' consensus of $336.01 which suggests that it could grow by 16.14%. Given that Cellectar Biosciences has higher upside potential than Insulet, analysts believe Cellectar Biosciences is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLRB
    Cellectar Biosciences
    2 2 0
    PODD
    Insulet
    15 2 0
  • Is CLRB or PODD More Risky?

    Cellectar Biosciences has a beta of 0.507, which suggesting that the stock is 49.315% less volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

  • Which is a Better Dividend Stock CLRB or PODD?

    Cellectar Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLRB or PODD?

    Cellectar Biosciences quarterly revenues are --, which are smaller than Insulet quarterly revenues of $569M. Cellectar Biosciences's net income of -$6.6M is lower than Insulet's net income of $35.4M. Notably, Cellectar Biosciences's price-to-earnings ratio is -- while Insulet's PE ratio is 52.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences is 137.94x versus 9.73x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLRB
    Cellectar Biosciences
    137.94x -- -- -$6.6M
    PODD
    Insulet
    9.73x 52.04x $569M $35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock